DOH Abu Dhabi and Sanofi plan vaccine centre with 5 capabilities for UAE clinics

Department of Health – Abu Dhabi (DOH Abu Dhabi) and Sanofi signed a 23 June 2026 memorandum of understanding to explore a Vaccine Innovation Centre in Abu Dhabi, with potential effects on UAE clinics, insurers and patients as new vaccines move closer to local research, clinical development and manufacturing.

For Dubai operators regulated by the Dubai Health Authority (DHA), the immediate issue is market readiness rather than compliance. Any clinic offering vaccination, travel medicine, family medicine, paediatrics or occupational health should track whether the Abu Dhabi work creates new trial recruitment routes, storage requirements, patient consent workflows or payer coverage questions. In Abu Dhabi, DOH Abu Dhabi will have the first regulatory line of sight. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, Ministry of Health and Prevention (MOHAP) rules will remain the reference point for licensed providers.

What DOH Abu Dhabi and Sanofi agreed

The agreement, announced during the BIO International Convention 2026 in San Diego, builds on a 2025 DOH Abu Dhabi-Sanofi partnership and sits within Abu Dhabi’s Health, Endurance, Longevity and Medicine (HELM) Cluster, according to the DOH Abu Dhabi announcement.

DOH Abu Dhabi said the proposed centre would bring together five areas that matter to operators:

• AI-enabled vaccine discovery and design
• Immunology
• Clinical development
• mRNA research
• Clinical manufacturing

“single ecosystem designed to accelerate the journey from discovery to impact.”
H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary, DOH Abu Dhabi

Baptiste de Clarens, General Manager Vaccines, Greater Gulf at Sanofi, said vaccine innovation is being reshaped by artificial intelligence, mRNA science and models that connect discovery, development and manufacturing. For UAE providers, that points to a future pathway where clinical trial capability, data quality and cold-chain discipline become commercial differentiators.

Why clinics and insurers should care

For clinics, the first practical question is eligibility to participate in research or delivery programmes. A Dubai or Abu Dhabi clinic should audit its adult and paediatric vaccine workflow before any centre becomes operational: doctor licensing, nurse competency, anaphylaxis response, vaccine refrigerator logs, adverse-event reporting, consent forms and electronic medical record fields. The highest-risk gap is documentation, because vaccine lots, batch numbers, expiry dates and patient eligibility must be auditable.

For insurers, the question is benefit design. Daman, Thiqa and Sukoon coverage positions should be checked against policy wording, network circulars and prior-approval rules before clinics quote patients. Routine vaccines, travel vaccines, employer-paid vaccines and newly introduced advanced vaccines can sit in different benefit buckets. A clinic should confirm three items before launch: covered indication, age eligibility and reimbursement code.

Price signals are still local and product-specific. Operators should avoid quoting a fixed market price from the DOH Abu Dhabi-Sanofi announcement, because the MoU did not publish tariff data. The actionable route is to check the provider’s DHA, DOH Abu Dhabi or MOHAP licence scope, then review each payer contract, pharmacy purchase price and any applicable public programme before setting a patient cash price in AED.

What to watch next

The next operator-relevant signal will be whether DOH Abu Dhabi and Sanofi move from MoU to a formal centre agreement, publish a site, name clinical partners or announce trial protocols. Clinic CEOs should watch for partnership slots. CIOs should watch for data capture and interoperability requirements. CFOs should model staff training, vaccine storage, wastage and reimbursement lag before adding new vaccine lines.

Patients may benefit if more advanced vaccines are researched, tested or manufactured in the UAE, but access will still depend on regulator approval, clinical indication and payer coverage. Dubai clinics should continue to follow DHA rules. Abu Dhabi and Al Ain providers should follow DOH Abu Dhabi. Northern emirates providers should follow MOHAP. To find licensed clinics and providers, use the UAE Open Healthcare Directory as the practical starting point before booking or benchmarking services.